Still Independent, Shire Continues With Goals Modeled On Celgene, Gilead, Biogen Idec
This article was originally published in The Pink Sheet Daily
Executive Summary
While the proposed merger with AbbVie, abandoned on Oct. 20, took a lot of energy, it did not deter Shire from pursuing its stated strategy, CEO Ornskov tells “The Pink Sheet” DAILY. The specialty firm reported a strong third quarter, with rare disease product sales up 66%.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.